Navigation Links
NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa
Date:9/22/2010

y markets with strong economic growth and increased demand for improved health care and more effective products. We strongly believe that Abstral™ has a great potential in the territory and will contribute significantly to physicians' abilities to treat patients experiencing breakthrough cancer pain, hence improving quality of life for these patients."

Torbjorn Bjerke President and CEO of Orexo

"This agreement with NewBridge will enable sales of Abstral™ in additional geographic territories and is another step in developing Abstral™ into a global brand. Our partnership with NewBridge will allow Abstral™ to be available for thousand of doctors to help them manage patients suffering breakthrough cancer pain."

About Abstral™

Abstral™ is a fast-dissolving tablet for sub-lingual administration of fentanyl, intended for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. It is based on Orexo's unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. Currently Abstral™ is sold in fourteen countries in Europe, and reached sales of 7.4 M pounds in the first half of 2010.

About Breakthrough Cancer Pain

Breakthrough pain ("BTP") is an acute and often severe flare of pain experienced by patients suffering from cancer that occurs even though a person may be taking opioid pain relief medicine regularly for their persistent pain. It is known as breakthrough pain because it is pain that "breaks through" a regular pain medicine schedule. It may be caused by the cancer itself or it may be related to cancer treatment. For some people, breakthrough pain occurs during certain everyday activities, such as walking or dressing. For others, it occurs unexpectedly without any apparent cause.

Between 64% and 89% o
'/>"/>

SOURCE NewBridge Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Pharmaceutical Industry in China to 2020: ... Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, ... offering. This report tackles not ... China but also home grown companies ...
(Date:7/28/2015)... YORK , July 28, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Human Insulin Market ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/28/2015)... ... 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim is now ... and reduces the appearance of fine lines and wrinkles. , According to the Allergan ... add volume to your cheek area to correct age-related volume loss in adults over ...
(Date:7/28/2015)... ... 28, 2015 , ... On July 16th NPR reported needle exchange ... proposed bills and laws revolving the implementation of a small pilot program in Miami-Dade ... are continuing to hand out clean needles to drug users who are addicted to ...
(Date:7/28/2015)... PAUL, Minn. (PRWEB) , ... July 28, 2015 ... ... workflow company Kinetic Data announced that Schneider Electric has completed its upgrade ... Electric is a global organization with more than 170,000 employees in 134 countries ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... , ... Women fear developing Alzheimer's disease more than having a heart attack ... are treatable, but there is little an individual can do to arrest the progress ... clinical trial, reports the July 2015 Harvard Women's Health Watch . , "There ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that effective with the ... for Pyratine-6(TM), all promotion, sales and distribution of,Pyratine-6(TM) ... Company., Phil Rose, Senetek,s Chief Operating Officer ...
... 1 UTC Power, a United,Technologies Corp. (NYSE: ... Hospital in California,s Napa Valley with its new, next-generation,fuel ... in full,production in the summer of 2009., St. ... of Adventist Health, a not-for-profit health care system operating ...
... RGEN ) announced today that Dr. Alfred L. Goldberg, ... Goldberg is currently a Professor of,Cell Biology at Harvard ... for elucidating the structure and function of the proteasome,which ... in,cells. In addition, he has made major contributions to ...
... increase as women go through menopause according to ... earlier than planned also increases through late perimenopause ... is published in the July 1 issue of ... especially problems staying asleep, are relatively prevalent concerns ...
... direct marketing promotional products company, is tapped in to a network ... products. , ... Lewiston, ME (PRWEB) July 1, 2008 ... on its Web site, Crestline Custom Imprinted Products, a direct marketing ...
... as new surgical procedures are,breaking ground daily in ... breaking ground for patients. LipoVance.com,( http://www.LipoVance.com ) is ... it is offering an unprecedented $800 coupon,toward liposuction ... "In today,s troubled economy," said Kevin Gaines ...
Cached Medicine News:Health News:Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM) 2Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Sleep problems associated with menopause vary among ethnic groups 2Health News:Crestline Has Access to Hundreds of Thousands of Items 2Health News:The Shape of Things to Come: Website Gives the Lowdown on Liposuction, Pioneers the Field by Offering Consumers $800 Coupons Toward Procedures 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: